|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Hematocrit procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Corpuscular Hemoglobin Concentration Mean
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Corpuscular Hemoglobin Concentration Mean
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Seventy-five genetic loci influencing the human red blood cell.
|
23222517 |
2012 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
106 primary ITP patients (16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
|
31840311 |
2020 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Primary intestinal Epstein-Barr virus [EBV]-associated natural killer/T-cell lymphoproliferative disorder [PIEBV+ NK/T-LPD] is a rare clinical entity, which is difficult to differentiate from inflammatory bowel disease [IBD].
|
29635312 |
2018 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders (EBV<sup>+</sup> T/NK LPD) encompass a heterogeneous group of disorders, including chronic active Epstein-Barr virus infection (CAEBV), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), systemic EBV<sup>+</sup> T-cell lymphoma of childhood and hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) and so on, predominantly affecting children and young adults with high mortality.
|
30356785 |
2018 |
|
Adrenoleukodystrophy
|
0.070 |
Biomarker
|
disease |
BEFREE |
We show that the Drosophila bubblegum(bgm) and double bubble(dbb) genes have overlapping functions, and that the consequences of double knockout of both bubblegum and double bubble in the fly brain are profound, affecting behavior and brain morphology, and providing the best paradigm to date for an animal model of adrenoleukodystrophy (ALD), a fatal childhood neurodegenerative disease associated with the accumulation of very-long-chain fatty acids.
|
26893370 |
2016 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
B cell subsets and function were analyzed in peripheral blood from 66 adult patients with primary SS (including 14 patients with B cell lymphoproliferative disease [LPD]) and 30 healthy donors, using flow cytometry, calcium mobilization, and gene array analysis.
|
23279883 |
2013 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus-positive T/natural killer (NK)-cell lymphoproliferative disorder (EBV+T/NK LPD) encompasses a heterogeneous group of disorders that have a common feature with excessive lymphoid proliferation of mainly T cells and/or NK cells.
|
24228130 |
2013 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Control donor-derived and T/NK-LPD-derived strains were similarly distributed across allelotypes and, by using allelic polymorphisms to track virus strains in patients pre- and post-haematopoietic stem-cell transplant, we show that a single strain can induce both T/NK-LPD and B-cell-lymphoproliferative disease in the same patient.
|
21248177 |
2011 |
|
Adrenoleukodystrophy
|
0.070 |
Biomarker
|
disease |
BEFREE |
Its mouse/human homologs, lipidosin/bubblegum, have been suggested to participate in X-linked adrenoleukodystrophy (X-ALD), an adreno/neurodegenerative disorder with accumulation of very long chain fatty acids (VLCFA) in tissues and plasma.
|
19167491 |
2009 |
|
Adrenoleukodystrophy
|
0.070 |
Biomarker
|
disease |
BEFREE |
ACSBG1, an acyl-CoA synthetase originally identified in the fruit fly mutant bubblegum, was hypothesized to contribute to the biochemical pathology of X-linked adrenoleukodystrophy.
|
16371355 |
2006 |
|
Adrenoleukodystrophy
|
0.070 |
AlteredExpression
|
disease |
LHGDN |
Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.
|
15800013 |
2005 |
|
Adrenoleukodystrophy
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
BG1 protein levels were similar in wild-type and X-ALD mouse brain, spinal cord, testis, and adrenal gland.
|
15464426 |
2005 |
|
Adrenoleukodystrophy
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.
|
15800013 |
2005 |
|
Adrenoleukodystrophy
|
0.070 |
Biomarker
|
disease |
BEFREE |
A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy.
|
12719378 |
2003 |
|
Adrenoleukodystrophy
|
0.070 |
Biomarker
|
disease |
BEFREE |
Thus, Lipidosin may mediate the link between ALDP dysfunction and the impairment of fatty acid metabolism in X-ALD.
|
11112418 |
2000 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Twelve cases of T gamma LPD (lymphoproliferative disorders of Fc gamma receptor-bearing T cells) involving an expansion of large granular lymphocyte/natural killer (LGL/NK) cells were investigated for the expression of LGL/NK-associated markers and for T beta gene rearrangement.
|
3934321 |
1985 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
A 13-year-old boy presented to our clinic with a raised tumor with PCSM-LPD histology and was successfully treated with ultra-low-dose radiation therapy.
|
30548331 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We have previously shown that the PEGylated LPD (liposome-polycation-DNA) nanoparticles were highly efficient in delivering siRNA to the tumor with low liver uptake.
|
19595666 |
2009 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
After withdrawal of MTX, 11 of the MTX-LPD cases showed a spontaneous regression of tumors.
|
17117491 |
2007 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
While p16/INK4a might play a role in the proliferative rate of LP-LPD, further investigations are needed to assess the clinical relevance of p16/INK4a expression in predicting the evolution of tumors and to explain how EBV could favor p16/INK4a protein accumulation in lesions.
|
10793069 |
2000 |